11:12 AM EST, 11/04/2024 (MT Newswires) -- Journey Medical ( DERM ) said Monday the US Food and Drug Administration approved Emrosi for the treatment of inflammatory lesions of rosacea, an inflammatory skin condition, in adults.

The company said it is completing the manufacturing of Emrosi for the US market, with initial supply expected to be available late in Q1 or early in Q2 2025.

Journey Medical ( DERM ) said it developed Emrosi in collaboration with Dr. Reddy's Laboratories (RDY).

Price: 5.33, Change: -0.84, Percent Change: -13.61